BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sun H, Kennedy WP, Wilbraham D, Lewis N, Calder N, Li X, Ma J, Yee KL, Ermlich S, Mangin E, Lines C, Rosen L, Chodakewitz J, Murphy GM. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep 2013;36:259-67. [PMID: 23372274 DOI: 10.5665/sleep.2386] [Cited by in Crossref: 11] [Cited by in F6Publishing: 48] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Sanchez-Alavez M, Benedict J, Wills DN, Ehlers CL. Effect of suvorexant on event-related oscillations and EEG sleep in rats exposed to chronic intermittent ethanol vapor and protracted withdrawal. Sleep 2019;42:zsz020. [PMID: 30715515 DOI: 10.1093/sleep/zsz020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
2 Banerjee I. Orexin Receptor Competitive Antagonists: A Novel target of the Sedative and hypnotics drugs for the pharmacotherapy of Insomnia. Nepal J Epidemiol 2018;8:713-5. [PMID: 30867974 DOI: 10.3126/nje.v8i1.21139] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Wrishko RE, McCrea JB, Yee KL, Liu W, Panebianco D, Mangin E, Chakravarthy M, Martinez-Cantarin MP, Kraft WK. Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects. Clin Drug Investig 2019;39:441-51. [PMID: 30810914 DOI: 10.1007/s40261-019-00764-x] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 Winrow CJ, Renger JJ. Discovery and development of orexin receptor antagonists as therapeutics for insomnia. Br J Pharmacol 2014;171:283-93. [PMID: 23731216 DOI: 10.1111/bph.12261] [Cited by in Crossref: 86] [Cited by in F6Publishing: 88] [Article Influence: 10.8] [Reference Citation Analysis]
5 Wozniak DR, Quinnell TG. Unmet needs of patients with narcolepsy: perspectives on emerging treatment options. Nat Sci Sleep 2015;7:51-61. [PMID: 26045680 DOI: 10.2147/NSS.S56077] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
6 Tabata H, Kuriyama A, Yamao F, Kitaguchi H, Shindo K. Suvorexant-Induced Dream Enactment Behavior in Parkinson Disease: A Case Report. J Clin Sleep Med 2017;13:759-60. [PMID: 28212694 DOI: 10.5664/jcsm.6600] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
7 Matsumura T, Terada J, Yoshimura C, Koshikawa K, Kinoshita T, Yahaba M, Nagashima K, Sakao S, Tatsumi K. Single-use suvorexant for treating insomnia during overnight polysomnography in patients with suspected obstructive sleep apnea: a single-center experience. Drug Des Devel Ther 2019;13:809-16. [PMID: 30880914 DOI: 10.2147/DDDT.S197237] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
8 Khoo SY, Brown RM. Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA? CNS Drugs 2014;28:713-30. [PMID: 24942635 DOI: 10.1007/s40263-014-0179-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
9 Callander GE, Olorunda M, Monna D, Schuepbach E, Langenegger D, Betschart C, Hintermann S, Behnke D, Cotesta S, Fendt M, Laue G, Ofner S, Briard E, Gee CE, Jacobson LH, Hoyer D. Kinetic properties of "dual" orexin receptor antagonists at OX1R and OX2R orexin receptors. Front Neurosci 2013;7:230. [PMID: 24376396 DOI: 10.3389/fnins.2013.00230] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
10 Neylan TC, Richards A, Metzler TJ, Ruoff LM, Varbel J, O'Donovan A, Sivasubramanian M, Motraghi T, Hlavin J, Batki SL, Inslicht SS, Samuelson K, Morairty SR, Kilduff TS. Acute cognitive effects of the hypocretin receptor antagonist almorexant relative to zolpidem and placebo: a randomized clinical trial. Sleep 2020;43:zsaa080. [PMID: 32303763 DOI: 10.1093/sleep/zsaa080] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
11 Fulcher BD, Phillips AJ, Postnova S, Robinson PA. A physiologically based model of orexinergic stabilization of sleep and wake. PLoS One 2014;9:e91982. [PMID: 24651580 DOI: 10.1371/journal.pone.0091982] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 4.1] [Reference Citation Analysis]
12 Murphy P, Moline M, Mayleben D, Rosenberg R, Zammit G, Pinner K, Dhadda S, Hong Q, Giorgi L, Satlin A. Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study. J Clin Sleep Med 2017;13:1289-99. [PMID: 29065953 DOI: 10.5664/jcsm.6800] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 10.0] [Reference Citation Analysis]
13 Herring WJ, Connor KM, Snyder E, Snavely DB, Zhang Y, Hutzelmann J, Matzura-Wolfe D, Benca RM, Krystal AD, Walsh JK, Lines C, Roth T, Michelson D. Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data. Psychopharmacology (Berl) 2017;234:1703-11. [PMID: 28265715 DOI: 10.1007/s00213-017-4573-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
14 Sandsmark DK, Elliott JE, Lim MM. Sleep-Wake Disturbances After Traumatic Brain Injury: Synthesis of Human and Animal Studies. Sleep 2017;40. [PMID: 28329120 DOI: 10.1093/sleep/zsx044] [Cited by in Crossref: 32] [Cited by in F6Publishing: 47] [Article Influence: 6.4] [Reference Citation Analysis]
15 Herring WJ, Connor KM, Snyder E, Snavely DB, Zhang Y, Hutzelmann J, Matzura-Wolfe D, Benca RM, Krystal AD, Walsh JK, Lines C, Roth T, Michelson D. Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials. J Clin Sleep Med 2016;12:1215-25. [PMID: 27397664 DOI: 10.5664/jcsm.6116] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
16 Hirano A, Hsu PK, Zhang L, Xing L, McMahon T, Yamazaki M, Ptáček LJ, Fu YH. DEC2 modulates orexin expression and regulates sleep. Proc Natl Acad Sci U S A 2018;115:3434-9. [PMID: 29531056 DOI: 10.1073/pnas.1801693115] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
17 Han Y, Yuan K, Zheng Y, Lu L. Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders. Neurosci Bull 2020;36:432-48. [PMID: 31782044 DOI: 10.1007/s12264-019-00447-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
18 Homolak J, Mudrovčić M, Vukić B, Toljan K. Circadian Rhythm and Alzheimer's Disease. Med Sci (Basel) 2018;6:E52. [PMID: 29933646 DOI: 10.3390/medsci6030052] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
19 Gotter AL, Garson SL, Stevens J, Munden RL, Fox SV, Tannenbaum PL, Yao L, Kuduk SD, McDonald T, Uslaner JM, Tye SJ, Coleman PJ, Winrow CJ, Renger JJ. Differential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulators. BMC Neurosci 2014;15:109. [PMID: 25242351 DOI: 10.1186/1471-2202-15-109] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
20 Matzeu A, Martin-Fardon R. Targeting the Orexin System for Prescription Opioid Use Disorder. Brain Sci 2020;10:E226. [PMID: 32290110 DOI: 10.3390/brainsci10040226] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
21 Tannenbaum PL, Tye SJ, Stevens J, Gotter AL, Fox SV, Savitz AT, Coleman PJ, Uslaner JM, Kuduk SD, Hargreaves R, Winrow CJ, Renger JJ. Inhibition of Orexin Signaling Promotes Sleep Yet Preserves Salient Arousability in Monkeys. Sleep 2016;39:603-12. [PMID: 26943466 DOI: 10.5665/sleep.5536] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
22 Ishibashi Y, Nishitani R, Shimura A, Takeuchi A, Touko M, Kato T, Chiba S, Ashidate K, Ishiwata N, Ichijo T, Sasabe M. Non-GABA sleep medications, suvorexant as risk factors for falls: Case-control and case-crossover study. PLoS One 2020;15:e0238723. [PMID: 32916693 DOI: 10.1371/journal.pone.0238723] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
23 Boutrel B, Steiner N, Halfon O. The hypocretins and the reward function: what have we learned so far? Front Behav Neurosci 2013;7:59. [PMID: 23781178 DOI: 10.3389/fnbeh.2013.00059] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
24 Uslaner JM, Herring WJ, Coleman PJ. The Discovery of Suvorexant: Lessons Learned That Can Be Applied to Other CNS Drug Development Efforts. ACS Pharmacol Transl Sci 2020;3:161-8. [PMID: 32259095 DOI: 10.1021/acsptsci.9b00110] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Roehrs T, Withrow D, Koshorek G, Verkler J, Bazan L, Roth T. Sleep and pain in humans with fibromyalgia and comorbid insomnia: double-blind, crossover study of suvorexant 20 mg versus placebo. J Clin Sleep Med 2020;16:415-21. [PMID: 31992394 DOI: 10.5664/jcsm.8220] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Vermeeren A, Sun H, Vuurman EF, Jongen S, Van Leeuwen CJ, Van Oers AC, Palcza J, Li X, Laethem T, Heirman I, Bautmans A, Troyer MD, Wrishko R, McCrea J. On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers. Sleep 2015;38:1803-13. [PMID: 26039969 DOI: 10.5665/sleep.5168] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
27 Sun Y, Tisdale RK, Kilduff TS. Hypocretin/Orexin Receptor Pharmacology and Sleep Phases. Front Neurol Neurosci 2021;45:22-37. [PMID: 34052813 DOI: 10.1159/000514963] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
28 Rainero I, Rubino E, Paemeleire K, Gai A, Vacca A, De Martino P, Gentile S, Sarchielli P, Pinessi L. Genes and primary headaches: discovering new potential therapeutic targets. J Headache Pain 2013;14:61. [PMID: 23848401 DOI: 10.1186/1129-2377-14-61] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
29 Roecker AJ, Cox CD, Coleman PJ. Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. J Med Chem 2016;59:504-30. [PMID: 26317591 DOI: 10.1021/acs.jmedchem.5b00832] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 8.9] [Reference Citation Analysis]
30 Vermeeren A, Vets E, Vuurman EF, Van Oers AC, Jongen S, Laethem T, Heirman I, Bautmans A, Palcza J, Li X, Troyer MD, Wrishko R, McCrea J, Sun H. On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly. Psychopharmacology (Berl) 2016;233:3341-51. [PMID: 27424295 DOI: 10.1007/s00213-016-4375-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
31 Chow M, Cao M. The hypocretin/orexin system in sleep disorders: preclinical insights and clinical progress. Nat Sci Sleep 2016;8:81-6. [PMID: 27051324 DOI: 10.2147/NSS.S76711] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
32 Sorooshyari S, Huerta R, de Lecea L. A Framework for Quantitative Modeling of Neural Circuits Involved in Sleep-to-Wake Transition. Front Neurol 2015;6:32. [PMID: 25767461 DOI: 10.3389/fneur.2015.00032] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
33 Sieminski M, Szypenbejl J, Partinen E. Orexins, Sleep, and Blood Pressure. Curr Hypertens Rep. 2018;20:79. [PMID: 29992504 DOI: 10.1007/s11906-018-0879-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
34 Gotter AL, Forman MS, Harrell CM, Stevens J, Svetnik V, Yee KL, Li X, Roecker AJ, Fox SV, Tannenbaum PL, Garson SL, Lepeleire ID, Calder N, Rosen L, Struyk A, Coleman PJ, Herring WJ, Renger JJ, Winrow CJ. Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to Man. Sci Rep 2016;6:27147. [PMID: 27256922 DOI: 10.1038/srep27147] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 6.3] [Reference Citation Analysis]
35 Ito H, Ogawa Y, Shimojo N, Kawano S. Suvorexant Poisoning in a Patient With Cirrhosis and Renal Failure. Cureus 2021;13:e14329. [PMID: 33968537 DOI: 10.7759/cureus.14329] [Reference Citation Analysis]
36 Feng FF, Li JK, Liu XY, Zhang FG, Cheung CW, Ma JA. General Synthesis of Tri-Carbo-Substituted N2-Aryl-1,2,3-triazoles via Cu-Catalyzed Annulation of Azirines with Aryldiazonium Salts. J Org Chem 2020;85:10872-83. [PMID: 32691600 DOI: 10.1021/acs.joc.0c01433] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
37 Maehara S, Yuge N, Higashi C, Ota T, Furukawa J, Takeuchi T. Pharmacological characterization of a novel potent, selective, and orally active orexin 2 receptor antagonist, SDM-878. Neuropsychopharmacol Rep 2020;40:182-9. [PMID: 32337858 DOI: 10.1002/npr2.12105] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Sun H, Palcza J, Card D, Gipson A, Rosenberg R, Kryger M, Lines C, Wagner JA, Troyer MD. Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea. J Clin Sleep Med 2016;12:9-17. [PMID: 26194728 DOI: 10.5664/jcsm.5382] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
39 Saputra BD, Levita J, Mustarichie R. Efficacy, Safety, and Drug–Drug Interactions for Insomnia Therapy in COVID-19 Patients. JMDH 2022;Volume 15:137-52. [DOI: 10.2147/jmdh.s337053] [Reference Citation Analysis]
40 Zeitzer JM, Joyce DS, McBean A, Quevedo YL, Hernandez B, Holty JE. Effect of Suvorexant vs Placebo on Total Daytime Sleep Hours in Shift Workers: A Randomized Clinical Trial. JAMA Netw Open 2020;3:e206614. [PMID: 32484552 DOI: 10.1001/jamanetworkopen.2020.6614] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
41 Tamura K, Maruyama T, Sakurai S. Preventive Effect of Suvorexant for Postoperative Delirium after Coronary Artery Bypass Grafting. Ann Thorac Cardiovasc Surg 2019;25:26-31. [PMID: 30089761 DOI: 10.5761/atcs.oa.18-00038] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
42 Abad VC, Guilleminault C. Pharmacological treatment of sleep disorders and its relationship with neuroplasticity. Curr Top Behav Neurosci 2015;25:503-53. [PMID: 25585962 DOI: 10.1007/7854_2014_365] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
43 Norman JL, Anderson SL. Novel class of medications, orexin receptor antagonists, in the treatment of insomnia - critical appraisal of suvorexant. Nat Sci Sleep. 2016;8:239-247. [PMID: 27471419 DOI: 10.2147/nss.s76910] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
44 Pigeon WR, Bishop TM, Marcus JA. Advances in the management of insomnia. F1000Prime Rep 2014;6:48. [PMID: 24991425 DOI: 10.12703/P6-48] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
45 Equihua AC, De La Herrán-Arita AK, Drucker-Colin R. Orexin receptor antagonists as therapeutic agents for insomnia. Front Pharmacol 2013;4:163. [PMID: 24416019 DOI: 10.3389/fphar.2013.00163] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
46 Lee-Iannotti JK, Parish JM. Suvorexant: a promising, novel treatment for insomnia. Neuropsychiatr Dis Treat 2016;12:491-5. [PMID: 26955275 DOI: 10.2147/NDT.S31495] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
47 Rihel J, Schier AF. Sites of action of sleep and wake drugs: insights from model organisms. Curr Opin Neurobiol 2013;23:831-40. [PMID: 23706898 DOI: 10.1016/j.conb.2013.04.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
48 Hassinger AB, Bletnisky N, Dudekula R, El-Solh AA. Selecting a pharmacotherapy regimen for patients with chronic insomnia. Expert Opin Pharmacother 2020;21:1035-43. [PMID: 32202451 DOI: 10.1080/14656566.2020.1743265] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Dubey AK, Handu SS, Mediratta PK. Suvorexant: The first orexin receptor antagonist to treat insomnia. J Pharmacol Pharmacother 2015;6:118-21. [PMID: 25969666 DOI: 10.4103/0976-500X.155496] [Cited by in Crossref: 36] [Cited by in F6Publishing: 10] [Article Influence: 5.1] [Reference Citation Analysis]
50 Cada DJ, Levien TL, Baker DE. Suvorexant. Hosp Pharm 2015;50:59-71. [PMID: 25684802 DOI: 10.1310/hjp5001-059] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
51 Hoyer D, Dürst T, Fendt M, Jacobson LH, Betschart C, Hintermann S, Behnke D, Cotesta S, Laue G, Ofner S, Legangneux E, Gee CE. Distinct effects of IPSU and suvorexant on mouse sleep architecture. Front Neurosci 2013;7:235. [PMID: 24368893 DOI: 10.3389/fnins.2013.00235] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
52 Kaufmann P, Ort M, Golor G, Kornberger R, Dingemanse J. First-in-human study with ACT-539313, a novel selective orexin-1 receptor antagonist. Br J Clin Pharmacol 2020;86:1377-86. [PMID: 32067262 DOI: 10.1111/bcp.14251] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
53 Ma J, Svetnik V, Snyder E, Lines C, Roth T, Herring WJ. Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects. Sleep 2014;37:1609-19. [PMID: 25197807 DOI: 10.5665/sleep.4068] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]